Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer

ABSTRACT: The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy compared to FOLFIRI in a phase III trial. Panitumumab with oxaliplatin- or irinotecan-based doublets is feasible and associated with improved activity in KRAS codon 12-13 wild-type patients. BRAF and other RAS rare mutations have been suggested as additional potential biomarkers for anti-EGFR agents in metastatic colo-rectal cancer. The present study aims to demonstrate the feasibility and the activity of the first-line combination of the GONO-FOLFOXIRI regimen and Panitumumab in molecularly selected metastatic colo-rectal cancer patients.

DISEASE(S): Metastatic Colorectal Carcinoma,Metastatic Colo-rectal Cancer,Colorectal Neoplasms

PROVIDER: 2107060 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Expression data collected using a custom Affymetrix array (Adenoma Biomarker Gene Chip) designed to differentiate neoplastic colorectal from non-neoplastic

Project description:This array was designed to verify a number of previously identified markers for colo-rectal adenoma. It contains probesets from the Affymetrix Hu133, HuGene and other novel probesets not included on other arrays.

2010-11-13 | GSE24713 | GEO

Expression data collected using a custom Affymetrix array (Adenoma Biomarker Gene Chip) designed to differentiate neoplastic colorectal from non-neoplastic

2010-11-13 | E-GEOD-24713 | biostudies-arrayexpress

Transcription profiling of human Caco2 cells treated withmesalazine

Project description:Several reports indicate that mesalazine (5-aminosalicylic acid or 5-ASA) is a promising candidate for the chemoprevention of Colo-Rectal Cancer (CRC) due to its ability to reach the purpose, yet avoiding at the same time the side effects that are usually determined by prolonged administrations of Non Steroidal Anti-Inflammatory Drugs. This activity of 5-ASA is probably the consequence of a number of effects determined on colon cancer cells and consisting of reduced proliferation, increased apoptosis and activation of cell cycle checkpoints. A recent observation has suggested that these effects could be mediated by the capacity of 5-ASA to interfere with the nuclear translocation of beta-catenin, in turn responsible for the inhibition of its transcription activity. The aim of our study was to better characterize the molecular mechanism by which 5-ASA inhibits the beta-catenin signaling pathway. To address this issue we assessed, by means of the Affymetrix microarray methodology, the transcriptome changes determined on Caco2 cells by a 96 h treatment with 20 mM mesalazine. Experiment Overall Design: We used the Affymetrix microarray methodology to assess the transcriptome changes determined on Caco2 cells by a 96 h treatment with 20 mM mesalazine. One sample was treated with mesalazine, and one sample was left untreated.

2010-02-17 | E-GEOD-14538 | biostudies-arrayexpress

Effect of mesalazine on Caco2 cells

2010-01-23 | GSE14538 | GEO

Expression data from Colossolactone H treated H1650 cells

Project description:Ganoderma colossum (Fr.) Baker, a white rot fungus distributed in tropical and subtropical forests, is a rare Ganoderma mushroom belonging to the family Ganodermataceae. In Asia, the fruiting body of G. colossum has been used as tonics or as folk medicine for a variety of illnesses, including malignant diseases. Colossolactone H (colo H) as a new compound was isolated and studied for its anticancer mechanism in human lung cancer H1650 cells. We used microarrays to analyze the gene expression changes upon colo H treatment that helped underlying the molecular mechanism of colo H in H1650 lung cancer cells. The H1650 cells treated with colo H for 12 and 24 h for RNA extraction and hybridization on Affymetrix microarrays.

2016-06-10 | E-GEOD-83161 | biostudies-arrayexpress

Expression data from Colossolactone H treated H1650 cells

2016-06-10 | GSE83161 | GEO

Effect of Orb2 depletion on mRNA expression in Drosophila larval brains

Project description:Regulation of codon optimality is an increasingly appreciated layer of cell- and tissue-specific protein expression control. Here, we use codon-modified reporters to show that differentiation of Drosophila neural stem cells into neurons enables protein expression from rare-codon-enriched genes. From a candidate screen, we identify the cytoplasmic polyadenylation element binding (CPEB) protein Orb2 as a positive regulator of rare-codon-dependent expression in neurons. Using RNA sequencing, we reveal that Orb2-upregulated mRNAs in the brain with abundant Orb2 binding sites have a rare-codon bias. From these Orb2-regulated mRNAs, we demonstrate that rare-codon enrichment is important for expression control and social behavior function of the metabotropic glutamate receptor (mGluR). Our findings reveal a molecular mechanism by which neural stem cell differentiation shifts genetic code regulation to enable critical mRNA and protein expression.

2024-04-09 | GSE263513 | GEO

Whole Metagenome Sequencing of colo-rectal cancer in Lynch Syndrome Patients

Project description:Whole Metagenome Sequencing of colo-rectal cancer in Lynch Syndrome Patients

| PRJEB70916 | ENA

Project description:Identification of Gut Microbiota Profile Associated with Colo-rectal Cancer in Saudi Population

| PRJNA1022861 | ENA

Predicting multi-class responses to preoperative chemoradiotherapy in rectal patients

Project description:The treatment strategy of rectal cancer has substantially changed in recent decades. Historically postoperative chemoradiotherapy (CRT) was considered to be the first-line therapy for stage II and III rectal cancers. However, the preoperative CRT is now considered to be the optimal therapy regimen for locally advanced rectal ancer due to its improved local control, reduced toxicity, and increased rate of sphincter preservation. Our study established a clinically practical multi-class prediction model by adopting a novel strategy that applies two separate prediction models (MI and TO predictor) sequentially to a patient to predict the response. For promising clinical practice, we validated our model in a published dataset, which is completely independent dataset from ours. This study suggests a clinically plausible prediction model that correctly infers the preoperative CRT response of patients with high accuracy based on 163 gene signatures we identified. Total RNAs were isolated from primary rectal tumor tissues of 69 patients who underwent chemoradiation therapy (CRT). These patients are classified into four different CRT responses: minimal response (MI), moderate response (MO), near total response (NT) and total response (TO). All the RNAs were subjected to microarray analysis using Affymetrix GenChip arrays.

2013-05-14 | E-GEOD-46862 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data